Donanemab Analyses Suggest Benefits for Select Alzheimer's Patients

Exploratory data suggest the drug's amyloid-lowering could last 4 years

Related Keywords

Judy George ,Alzheimer Disease Cooperative Study ,Alzheimer Disease Rating Scale ,Disease Assessment Scale Cognitive ,Disease Cooperative Study Instrumental Activities ,Daily Living ,Medpage Today ,